arrow
I

Inge Marie Svane

Lund University
H指数:70
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early discontinuation of immune checkpoint inhibitors after objective response in real-world melanoma: clinical and economic impact

黑色素瘤真实世界中客观缓解后免疫检查点抑制剂的早期停药:临床和经济影响

2026-10-220
OA
Corrigendum to “Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma” [Eur J Cancer 234 (2026) 116200]

勘误:“长期有效反应后停用BRAF/MEK抑制剂治疗:晚期黑色素瘤的临床结果”[Eur J Cancer 234 (2026) 116200]

2026-05-200
PRE
Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform

精准癌症医学平台中患者匹配类器官药物反应的免疫细胞调节

Cells
IF5.2
2026-01-300
OAAI
Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma

MM1636试验中IDO/PD-L1疫苗接种联合PD-1阻断疗法在一线转移性黑色素瘤中的五年临床结局及持久应答的免疫生物标志物

2025-12-140
OAAI
β-adrenergic signaling blockade attenuates metastasis through activation of cytotoxic CD4 T cells

β-肾上腺素能信号阻断通过激活细胞毒性CD4 T细胞来减弱转移

2025-11-170
OAAI
Nationwide Real-World Outcomes of Trial Eligible and Trial Ineligible Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab

全国范围内接受纳武利尤单抗联合伊匹木单抗治疗的、符合临床试验入组和不符合临床试验入组的转移性肾细胞癌患者的真实世界结局研究

2025-11-010
OA
Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score-matched survival analysis

达拉非尼联合曲美替尼与恩考拉非尼联合比美替尼在BRAF突变型转移性黑色素瘤中的比较:一项真实世界倾向性评分匹配的生存分析

2025-10-010
PRE
The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma

治疗前情绪困扰与肿瘤浸润淋巴细胞疗法对晚期黑色素瘤反应之间的关联

2025-07-130
PRE
Health-Related Quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared to ipilimumab in a randomized phase 3 trial

与健康相关的生活质量:比较接受肿瘤浸润淋巴细胞治疗的转移性黑色素瘤患者与接受ipilimumab治疗的随机III期试验

2025-06-180
PREAI
Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab

接受帕博利珠单抗抗PD-1检查点抑制剂免疫治疗的转移性黑色素瘤患者,且初始病情稳定的长期临床结局

2025-05-260
OA